Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 4Head & Neck 1Endocrine 1Breast 1

Conditions

Parathyroid Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Hyperparathyroidism, Primary 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × fluorocholine × Endocrine × Clear all
NCT07444723 2026-05-12

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

National Institutes of Health Clinical Center (CC)

Phase 2/3 Recruiting
193 enrolled
EndocrineHead & Neck

Parathyroid Neoplasms, Multiple Endocrine Neoplasia Type 1, Hyperparathyroidism, Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡